

Index

- Acute lymphoblastic leukemia detection, 90–91
- Affymetrix microarrays, 264
- Allelic discrimination methods, 277–280
- Amplification samples, issues in, 147–149
- Amplifluor primers, 31
- Amylolytic enzymes, 13
- Ancient DNA PCR analysis
 advantages in, 289–291
 applications in, 290–294
 contamination in, 287, 293–294
 contamination/sensitivity, 286–289
 genome sequences, 291, 293
 history, 284, 286, 290
 humans, 293–294
 overview, 284, 294–295
 phylogenetic relationships, 291–293
 vegetation, 293
- Antibiotic resistance, 179
- Antigen-based detection, 191–192
- Aptamer beacons, 34
- Archival material analysis. *See also*
 Formalin fixed paraffin embedded (FFPE) samples
 advantages, 255–256, 259–260
 influenza detection, 256–257
 injury minimization in, 258–259
 medical applications, 258
 molecular archaeology, 257–258
 overview, 254
 term definitions, 255
- ARTIs, 192–193
- Autism. *See* MMR vaccine/autism linkage
- Autoscaling, 120–122
- β -amylases, 13
- β -globin, 51–52, 59
- Bacteria detection, 173–174, 178–181
- Bacterial culture, 176, 179
- Bacteriophage Q β , 19–20
- BestKeeper, 117
- Biocatalysts, 12–13
- Biocompatibility issues, μ -TAS, 101
- Bioinformatics, 117–118
- Biosensors, molecular beacons as, 31–34
- Black hole quenchers, 27–28
- Bone marrow analysis in MRD detection, 156–157
- Breast cancer recurrence prediction (OncoType Dx), 11
- Buffers, 135
- Cancer detection
 clinical need for, 156–157
 conventional methods/limitations, 157–158, 255
 future developments, 164
 melanoma, 159–160, 162–163
 metastases, process of, 155
 PCR application in, 158
 prostate, 159–162
 prostate specific antigen, 161–162
 qRT-PCR in, 90
 tumor-associated wild-type mRNA, amplification of, 159–160
 tumor-specific abnormalities, amplification of, 158–159
- cDNA synthesis, 92–93
- Cell-free fetal DNA detection, 244–245
- Chamber-based stationary PCR, 97–98
- Chlamydia trachomatis*, 178
- Chronic myeloid leukaemia (CML), 129–130
- Cloning, 194–201
- Clostridium difficile*, 179–180
- Cluster analysis, 119–123
- Codelink microarrays, 264
- Computed tomography (CT), 157–158
- Contact quenching, 26–28
- Contamination
 ancient DNA analysis, 286–287, 289, 293–294
 MMR vaccine/autism linkage, 234–239
 overview, 7, 74–75, 198–199
 PCR product, 7, 74–75, 198–199, 286–289
 of primers, 198–199, 205
- Continuous-flow PCR, 53–54, 98–99

- Cy dyes, 263
Cytology, 157–158
- Dabcyl, 26–28
Dark quenchers, 76–77, 201–202
Detection of DNA
 dark quenchers, 76–77, 201–202
 ethidium bromide, 71–72, 75–76
 fluorescent labeling in, 73–74, 76
 μ -TAS issues, 101
 oligonucleotide conjugates, 76
 radiolabeling, 71
 trace fragments, 72–73
 UV light, 71
DHPLC in heterozygote scanning, 61–63
Digital PCR, 118
DNA amplification, 280–281
DNA fingerprint analysis
 applications of, 130–131, 142–143
 overview, 131–132
DNA polymerases
 Klenow fragment, 134–135
 PCR applications, 14–16
 Pfu, 13, 16
 pol I, 15
 Pwo, 16
 reaction mixes, 113
 Taq, 13–16, 57, 134–135
 Vent, 13
Dot blots, 5–6
Drug development, 197–198
Dyes
 Cy, 263
 ethidium bromide, 9, 20, 71–72
 intercalating, 94, 112–113
 SYBR Green I, 58–60, 82, 112–113
- E. coli* ribonuclease III, 21
Eclipse quenchers, 27–28
EDANS, 25–27
ELISA, 177, 222
Elongation, 135–137
Emulsion PCR, 285, 291
Enzymes, thermostable, 16–17
Estrogen receptor alpha (ER α) assay, 114
Ethidium bromide, 9, 20, 71–72
Ewing's sarcoma detection, 157–159
EWS-ETS mRNA detection, 158–159
Expression profiling, 117–118
Extremophiles, 12–13
- False positive results, 146, 205
Fetal epigenetic markers, development of, 245–247
Fluorescent resonant energy transfer (FRET)
 development of, 9–10
 limitations of, 26–28
 in molecular beacons, 24–28, 32–33
Fold changes, 266–268
Follicular lymphoma detection, qRT-PCR in, 90–91
- Formalin fixed paraffin embedded (FFPE) samples. *See also* Archival material analysis
 benefits of, 85–86
 defined, 255
 limitations of, 10
FRET. *See* Fluorescent resonant energy transfer (FRET)
Fungamyl, 13
Fungi detection, 173–174
- Gel-shift assay, 4–5
Gene expression analysis history
 ethidium bromide (*See* Ethidium bromide)
 “gel-shift” assay, 4–5
 housekeeping genes, 6–7
 improvements in, 5–6
 non-stringent hybridization/washing, 4
 normalization genes, 10
 northern blots, 5–7
 overview, 3–4
 pre-PCR, 129–132
 radioactive labeling, 4
 TaqMan™ (*See* TaqMan™)
Gene-Trak Systems, 20
Gene transcriptional regulation, 4–5
Genetic markers
 aptamers, 34
 development of, 245–247
 fetal, development of, 245–247
 in HIV research, 141–142
 molecular beacons (*See* Molecular beacons)
 SNPs, 143–144, 277, 280–281
 STRP, 277
Genome sequence analysis, 293
geNorm, 117
Giemsa banding, 129–130
Global pattern recognition (GPR), 117
GoldenGate Assay, 280
Group B *Streptococci* detection, 37
- HCoV-NL63, 204–205
Helicase dependent amplification (HDA), 17
Hepatitis C, 177
Heterozygotes
 distinguishing, 59–61, 63–65
 scanning, 61–63
Hierarchical clustering, 119–120
HIV research
 diagnostic techniques, 175–178
 genetic markers in, 141–142
 history of, 7–8
 molecular beacons in, 19–20, 25–26
 qRT-PCR in, 90
H5N1 178
Homozygotes, distinguishing, 59–61, 63–65

- Hot start protocol, 138
- Housekeeping genes, 6–7
- Human bocavirus (HBoV), 192–193, 207–208
- Human DNA analysis, ancient, 291, 293–294
- Human metapneumovirus (hMPV), 191
- Immunocytology, 157–158
- Immunofluorescence, 222
- Immunohistochemistry, 157–158, 255
- Immunological testing, 177
- Infectious disease detection
 - archival material analysis (*See* Archival material analysis)
 - bacteria, 173–174, 178–181
 - diagnostic techniques, 175–176
 - disease management, 174
 - fungi, 173–174
 - HIV (*See* HIV research)
 - influenza, 90, 178
 - malaria, 175–176, 184–185
 - organism classification, 173–174
 - overview, 141–142, 173
 - protozoa, 173–174, 184–185
 - research, history of, 7–8, 19–20, 25–26
 - sensitivity/specificity in, 174–175
 - viruses, 173–174, 176–178
- Influenza detection
 - archival analysis, 256–257
 - diagnostic techniques, 178
 - qRT-PCR in, 90
- Intercalating dyes, 94, 112–113
- KI polyomavirus, 205–207
- Klenow fragment, 134–135
- Labeling
 - fluorescent, 73–74, 76
 - molecular beacons (*See* Molecular beacons)
 - radioactive, 4
- LATE-PCR, 36–37
- LightCycler probes, 24, 199
- Linear hydrolysis probes, 140
- LUX primers, 31
- Magnetic resonance imaging (MRI), 157–158
- Malaria diagnostic techniques, 175–176, 184–185
- MAQC project, 265–266
- Measles virus, 230–232
- Medication, personalized, 103, 143–144
- Melanoma detection, 159–160, 162–163
- Melting analysis/rapid PCR
 - genotyping by probe melting, 63–65
 - heterozygote scanning, 61–63
 - high resolution, 59–61
 - overview, 57–58
 - PCR product, 58–59
- Metastases, process of, 155
- Methylation-specific PCR, 245–247
- Micro total analysis system (μ -TAS)
 - constraints, 100–101
 - overview, 96, 99–100, 102
- Microarrays
 - applications of, 124, 205
 - complex tissues, dilution effects, 271–272
 - data correlation/quality control, 265–267
 - fold-changes, 266–268
 - history of, 5–6
 - molecular beacons on, 33–34
 - normalization of, 267–270, 272
 - overview, 262–264, 272–273
 - PCR-CGE, 100
 - qPCR vs., 81
 - unregulated genes, 267–270, 272
- MicroRNA (miRNA) expression analysis
 - challenges in, 81
 - controls, 84–85
 - overview, 80, 85–86
 - percussor detection, 81–82
 - poly(A) tail mediated RT, 82–83
 - RT primer detection, 82
 - stem-loop primer mediated RT, 83–84
 - stem-loop primer multiplexing, 84
- Microscopy, 175–177
- Microsystem rapid PCR, 53–54
- Miniaturized quantitative clinical diagnostics
 - achievement of, 95
 - applications, 102, 258–259
 - benefits of, 96
- Minimal residual disease (MRD) detection
 - clinical need for, 156–157
 - qRT-PCR in, 90–91, 158
 - tumor-associated wild-type mRNA, amplification of, 159–160
- MIQE, 241
- miRNA. *See* MicroRNA (miRNA) expression analysis
- MMR vaccine/autism linkage
 - contamination issues, 234–239
 - experimental controls in, 145–146, 232–233
 - experimental setup issues, 232–235, 239
 - measles virus, 230–232
 - overview, 229–231
 - refutation of, 239–240
 - reproducibility, 234–237, 239
- Molecular archaeology, 257–258
- Molecular beacons
 - amplifiable probes, issues with, 21
 - applications of, 36–37
 - aptamer beacons, 34
 - as biosensors, 31–34
 - challenges, 23–24, 33

- Molecular beacons (*cont.*)
 exponential amplification assays, 20
 fluorescence, 24–26, 32–33
 on microarrays, 33–34
 mRNA visualization in vivo, 34–35
 multicolor probes, 26–28, 32–33
 overview, 19–20, 140
 RT-PCR assays, 28–29
 smart probes, 21–23
 specificity of, 29–31
- Molecular diagnostic papers, experimental considerations, 183
- Molecular Inversion Probe (MIP) Assay, 280
- Molecular switches, 21–23
- mRNA visualization in vivo, 34–35
- MRSA diagnosis, 176
- Multiplex PCR, 192–193, 279, 285, 290
- Mutations
 detecting via molecular beacons, 29–30
 detecting via rapid PCR, 61–63
 PCR analysis of, 179
- NASBA assays, molecular beacons in, 36–37
- Neandertal bone analysis, 257–258
- Neisseria gonorrhoeae*, 178
- Neuroblastoma detection, 159–161
- Newly identified viruses (NIVs), 191, 203–206, 208
- NimbleGen microarrays, 264
- Non-specific priming, prevention of, 138
- Normalization
 genes, 10
 of microarrays, 267–270, 272
 optimization of, 116–117, 119
 of qPCR, 94–95, 267–268, 270, 272
 quantitative clinical diagnostics, 94–95
- Northern blots, 5–7
- Oligonucleotides
 conjugates, 76
 as primers, 196–197
- Optimization of PCR
 amplification cycles, 137–138
 assay improvements, 112–114, 193–196
 assay variance/normalization, 116–117, 119
 bioinformatics, 117–118
 cluster analysis, 119–123
 efficiency, 115–116
 expression profiling, 117–118
 future directions, 118–120
 overview, 110–111, 124, 136
 pre-PCR steps, 111–112
 primers (*See* Primers)
 statistical analysis, 117–118
 strategy changes, 114–115
 system biology, 120–124
- Parainfluenza detection, qRT-PCR in, 90
- Paramyxoviruses, 196–197
- PaxGene system, 111
- PCP pneumonia, 184
- PCR
 advantages of, 289–291
 applications of, 76–77, 141–144, 291–294
 chamber-based stationary, 97–98
 continuous-flow, 53–54, 98–99
 development of, 132–135
 emulsion, 285, 291
 equilibrium vs. kinetic paradigms, 48–50
 false positive, 146, 205
 limitations of, 70–71, 144–145, 181–184, 191
 methylation-specific, 245–247
 multiplex, 192–193, 279, 285, 290
 optimization (*See* Optimization of PCR)
 overview, xiii, 13–14, 70
 plateau, 6–7, 56
 process overview, 133, 135–137, 139
 product contamination (*See* Contamination)
 safeguards, 145–150
 sensitivity (*See* Sensitivity)
 shunting, 98–99
 technique variations, 141
- Peripheral blood analysis in MRD detection, 156–157
- Personalized medication, 103, 143–144
- Pfu polymerase, 13, 16
- Philadelphia 1 chromosome, 129–130
- Phylogenetic relationship analysis, 291–293
- Picornaviruses, 196–197
- PLAC4* SNP detection, 247–249
- Pneumocystis jirovecii*, 184
- Pol I polymerase, 15
- Polymer-based electrophoresis microchips, 97
- Polymerase reaction mixes, 113
- Polyomavirus, 205–207
- Prenatal diagnosis
 cell-free fetal DNA, discovery of, 244
 cell-free fetal DNA, qRT-PCR detection of, 245
 fetal epigenetic markers, development of, 245–247
 overview, 243–244, 249–250
 trisomy 21 (Down's syndrome), 129–130, 247–249
- Primers
 allele-specific, 279–280
 amplifluor, 31
 ancient DNA analysis, 286–289
 contamination of, 198–199, 205
 LUX, 31
 non-specific, prevention of, 138
 oligonucleotides as, 196–197
 optimization of, 138–139
 scorpion, 31–32
 sequence targets for, 196

- TaqMan™ (See TaqMan™)
 in variation detection, 279
- Probes
 amplifiable, 21
 FRET, 93–94
 genotyping by, 63–65
 LightCycler, 24, 199
 linear hydrolysis, 140
 multicolor, 26–28, 32–33
 riboprobes, history of, 5–6
 scorpion, 140
 smart, 21–23
 tentacle, 32
- Promoter bashing, 4–5
- Prostate cancer detection, 159–160
- Prostate specific antigen detection, 161–162
- Protozoa detection, 173–174, 184–185
- Pseudomembranous colitis, 179–180
- Pullulanases, 13
- Pwo polymerase, 16
- Q-Gene, 118
- Q β replicase, 19–20
- qBASE, 117
- qPCR
 basis of, 20
 cDNA synthesis, 92–93
 denaturation, 55–56
 development of, 6–11
 efficiency, 115–116
 fold changes, 266–268
 FRET probes, 93–94
 intercalating dyes, 94
 limitations, 92
 μ -TAS in, 96, 99–101
 in microarray validation, 265–266
 microarrays vs., 81
 miRNA expression analysis
 (See MicroRNA (miRNA) expression analysis)
 normalization of, 94–95, 267–268, 270, 272
 overview, xiii–xiv, 85–86, 139–141
 quality control, 91–92
 quantitative clinical diagnostics
 (See quantitative clinical diagnostics)
 unregulated genes, 268–270, 272
- qRT-PCR
 bioinformatics, 117–118
 efficiency, 115–116
 expression profiling, 117–118
 limitations of, 202–203
 μ -TAS in, 99–100
 in MRD detection, 90–91, 158
 in PSA detection, 161–162
 in quantitative clinical diagnostics, 89–91
 relative quantification, 114–115
 SARS-CoV detection, 223
 sensitivity of, 110–111, 231
 statistical analysis, 117–118
 tyrosine hydroxylase detection, 160–161
- Quantitative clinical diagnostics
 applications, 90–91, 102
 cDNA synthesis, 92–93
 FRET probes, 93–94
 intercalating dyes, 94, 112–113
 limitations, 92
 μ -TAS in, 96, 99–102
 medication, personalized, 103, 143–144
 miniaturized (See Miniaturized quantitative clinical diagnostics)
 normalization, 94–95
 overview, 89, 103–104
 quality control, 91–92
- Radioactive labeling, 4
- Rapid PCR
 annealing, 56
 capillary tubes/hot air, 50
 denaturation, 55–56
 extension, 57
 instrumentation, 51–53
 melting analysis (See Melting analysis/rapid PCR)
 microsystem (continuous flow systems), 53–54
 optimal temperatures/times, 51–52, 54
 overview, 50, 65
 temperature profile, ideal, 54–55
 time minimization, 50–51
- Ras association domain family 1A (RASSF1A)*, 247
- Reaction mixes, 113
- Respiratory syncytial virus (RSV) detection, 90, 192–193
- Respiratory virus detection
 in drug development, 197–198
 fluorescence chemistry in, 201–202
 HBoV, 192–193, 207–208
 hMPV, 191
 NIVs, 191, 203–206, 208
 overview, 190–192, 194, 208–209
 paramyxoviruses, 196–197
 PCR benefits in, 192–193
 polyomavirus, 205–207
 primers in (See Primers)
 RSV, 90, 192–193
- REST, 118
- Retrovirus detection, qRT-PCR in, 90–91
- Riboprobes, history of, 5–6
- Ribotyping, 179–180
- Rifampicin resistance, 179
- RNA
 conversion of, to DNA template, 144
 degradation of, 11
 placental, detection of, 247–249
 purification techniques, history of, 5
 virus detection, 90–91

306 **Index**

- RNA*later* system, 111
 RT-PCR
 benefits of, 191, 199
 in cancer detection, 158–160
 cloning, 194–201
 costs, 200–201
 development of, 6–11
 molecular beacon assays, 28–29
 product contamination, 198–199
 quantitative competitive, 8
 sensitivity of, 199–200
 tyrosinase mRNA detection,
 162–163
 RT-qPCR. *See* qRT-PCR
- SARS coronavirus (SARS-CoV)
 antigen groups, 213–214
 characteristics of, 212–215, 217, 219,
 221, 223, 225, 227
 diagnosis/lab methods, 212, 221–223
 diagnosis/PCR methods, 212–213, 215,
 217, 219, 221, 223, 225, 227
 genome, 212–219, 221, 223, 225, 227
 taxonomy, 212–215, 217, 219, 221, 223,
 225, 227
 transmission, 219
 Scorpion primers, 31–32
 Scorpion probes, 140
 Self-organizing map method, 124
 Sensitivity
 ancient DNA analysis, 286–289
 in infectious disease detection,
 174–175
 of qRT-PCR, 110–111, 231
 of RT-PCR, 199–200
SERPINB5, 245–247
 Severe acute respiratory syndrome
 (SARS)
 diagnosis/lab methods, 212, 221–223
 diagnosis/PCR methods, 212–213, 215,
 217, 219, 221, 223, 225, 227
 overview, 212–213, 215, 217, 219, 221,
 223, 225, 227
 SARS-CoV (*See* SARS coronavirus
 (SARS-CoV))
 symptoms, 212, 221
 Short tandem repeat polymorphisms
 (STRPs), 277
 Short tandem repeats (STRs), 142
 Shotgun sequencing, 293
 Shunting PCR, 98–99
 Silicon/glass-based, 96–97
 Single nucleotide polymorphisms (SNPs),
 143–144, 277, 280–281
 Smart probes, 21–23
 Smoothing spline clustering (SSC)
 algorithm, 120
 Spanish flu. *See* Influenza detection
 Specificity, 29–31, 174–175
 Staining, 157–158 *See also* Dyes
- Statistical analysis, 117–118
 Stringency clamping, 29–30
 SYBR Green I, 58–60, 82, 112–113
 System biology, 120–124
- Taq polymerase, 13–16, 57, 134–135
 TaqMan™
 contact quenching by, 27–28
 in gene expression analysis, 9,
 112–113
 in respiratory virus detection, 201–202
 stem-loop primer mediated RT, 83–84
 stem-loop primer multiplexing, 84
 Tentacle probes, 32
 Termamyl, 13
 Thermostable enzymes
 future trends, 16–17
 overview, 12–13, 17
 PCR applications, 14–16
TMPRSS2 detection, 159
 Transcript expression levels, quantitative
 assessment of, 5–6
 Transgenic organisms, 16–17
 Trisomy 21 (Down's syndrome), 129–130,
 247–249
 Troubleshooting
 amplification samples, 147–149
 false positive results, 146, 205
 sample purity, 149–150
 variability, 146–147
 Tuberculosis
 diagnostic techniques, 175–176,
 178–181
 management, 174
 mutation analysis, 179
 PCR's future role in, 185–186
 VNTR as diagnostic tool, 180–181
 Twins, genotypic/phenotypic variations in,
 130
 Tyrosinase mRNA detection, 162–163
 Tyrosine hydroxylase detection in
 neuroblastoma, 160–161
- Uhlmann paper. *See* MMR vaccine/autism
 linkage
- Variability, issues in, 146–147
 Variable number tandem repeats (VNTRs),
 130–131, 180–181
 Variation, detection of, 276–281
 Vegetation analysis, 293
 Vent, 13
 Viruses
 detection of, 173–174, 176–178
 human bocavirus, 192–193, 207–208
 human metapneumovirus,
 191
 isolation, SARS-CoV, 222
 measles, 230–232
 NIVs, 191, 203–206, 208

Cambridge University Press

978-0-521-88231-6 - The PCR Revolution: Basic Technologies and Applications

Edited by Stephen A. Bustin

Index

[More information](#)**Index**

307

- paramyxoviruses, 196–197
- picornaviruses, 196–197
- polyomavirus, 205–207
- respiratory (*See* Respiratory virus detection)
- retrovirus detection, 90–91
- RNA, detection of, 90–91
- RSV detection, 90, 192–193
- SARS-CoV (*See* SARS coronavirus (SARS-CoV))
- WU polyomavirus, 205–207
- Xylanases, 13